CORONA Remedies Board of Directors
Get the latest insights into the leadership at CORONA Remedies. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Kirtikumar Laxmidas Mehta | Chairman |
| Niravkumar Kirtikumar Mehta | Managing Director & Chief Executive Officer |
| Ankur Kirtikumar Mehta | Joint Managing Director |
| Viral Bhupendrabhai Sitwala | Whole Time Director |
| Ameetkumar Hiranyakumar Desai | Non Executive Independent Director |
| Monica Hemal Kanuga | Non Executive Independent Director |
| Shirish Gundopant Belapure | Non Executive Independent Director |
| Bhaskar Vemban Iyer | Non Executive Independent Director |
| Chetna Prabhatkumar Dharajiya | Company Secretary & Compliance Officer |
CORONA Remedies FAQs
The board at CORONA Remedies consists of experienced professionals, including Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and others, overseeing the company’s strategic and corporate governance.
Directors at CORONA Remedies are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Kirtikumar Laxmidas Mehta is the current chairman at CORONA Remedies.
Executive directors at CORONA Remedies are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, CORONA Remedies adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At CORONA Remedies, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
